183 related articles for article (PubMed ID: 36897753)
1. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
4. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Devineni D; Polidori D
Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
[TBL] [Abstract][Full Text] [Related]
6. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin: A Review in Type 2 Diabetes.
Deeks ED; Scheen AJ
Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
[TBL] [Abstract][Full Text] [Related]
8. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
11. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
Scheen AJ
Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
[TBL] [Abstract][Full Text] [Related]
14. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
17. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
Vallon V; Thomson SC
Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
[No Abstract] [Full Text] [Related]
18. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Sen T; Ju W; Nair V; Ladd P; Menon R; Otto EA; Pyle L; Vigers T; Nelson RG; Arnott C; Neal B; Hansen MK; Kretzler M; Bjornstad P; Heerspink HJL
Kidney Int; 2023 Oct; 104(4):828-839. PubMed ID: 37543256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
